Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on August 7th, 2023%
Initial findings from a large clinical trial testing a vaccine against the chikungunya virus show the vaccine generates protective antibodies in the vast majority of recipients. . . . → Read More: Trial Shows Vaccine Induces Chikungunya Immune Response
By Alan, on August 3rd, 2023%
A clinical trial assessing a synthetic antibody to generate an immediate response and also generate a more durable treatment for solid tumor cancers, advanced to a mid-stage study. . . . → Read More: Trial Advances of Dual-Action Cancer Immunotherapy
By Alan, on July 28th, 2023%
The U.S. Food and Drug Administration issued new regulatory guidance for clinical trials of medical devices designed to prevent or treat opioid use disorder. . . . → Read More: FDA Issues Guidance for Opioid Therapy Device Trials
By Alan, on July 26th, 2023%
A treatment for depression designed as a game for patients will be assessed in a clinical trial conducted by a university psychology lab and funded by National Institutes of Health. . . . → Read More: NIH Funds Depression Game Therapy Clinical Trial
By Alan, on July 25th, 2023%
A biotechnology company creating living tissue from a person’s stem cells says it received FDA clearance for a clinical trial of its replacement knee cartilage. . . . → Read More: Trial Cleared for Lab-Grown Replacement Knee Cartilage
By Alan, on July 21st, 2023%
A biotechnology company designing immunotherapies for solid tumor cancers with a patient’s white blood cells is raising $80 million in its initial public offering or IPO. . . . → Read More: Cancer Immunotherapy Biotech Issues $80M IPO
By Alan, on July 20th, 2023%
A treatment for HIV taken just once, using the genome-editing technology Crispr, is receiving fast-track designation from the U.S. Food and Drug Administration. . . . → Read More: One-Time Crispr HIV Therapy Given Fast-Track Status
By Alan, on July 18th, 2023%
A clinical trial, testing stem cells for neurons fortified with tumor-killing viruses, administered its first doses to a patient with glioma, an aggressive type of brain cancer. . . . → Read More: Trial Underway Testing Engineered Cancer-Killing Viruses
By Alan, on July 17th, 2023%
A biopharmaceutical company and university neuroscience lab are collaborating on a clinical trial testing a peptide nasal spray treatment for social anxiety disorder. . . . → Read More: Drug Maker, Univ. Lab Partner on Neuropeptide Anxiety Trial
By Alan, on July 12th, 2023%
A clinical trial is recruiting participants to assess the safety and feasibility of a system for spray drying and re-constituting a person’s blood plasma. . . . → Read More: Trial Underway Testing Dried Plasma for Transfusions
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|